ReviewHematology. American Society of Hematology. Education Program2011
Eosinophilic myeloproliferative disorders.
Review in Hematology. American Society of Hematology. Education Program, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Four challenging cases of eosinophilic endocarditis or myocarditis with literature review.Journal of cardiothoracic surgery · 2025Review
- Molecular Pathogenesis and Treatment Perspectives for Hypereosinophilia and Hypereosinophilic Syndromes.International journal of molecular sciences · 2021Review
- A case report of Löffler endocarditis in idiopathic hypereosinophilic syndrome: recovery is possible.European heart journal. Case reports · 2018Article
- Leveraging Siglec-8 endocytic mechanisms to kill human eosinophils and malignant mast cells.The Journal of allergy and clinical immunology · 2018Article
- Is this still just sarcoidosis, or should we a-DRESS a different diagnosis?BMJ case reports · 2015Article
- Spinal Myeloid Sarcoma "Chloroma" Presenting as Cervical Radiculopathy: Case Report.Global spine journal · 2015Article
- Targeting self-renewal pathways in myeloid malignancies.Cell communication and signaling : CCS · 2013Article
- Chronic Eosinophilic Leukemia-Not Otherwise Specified (NOS) in the Background of a Large Cell Lymphoma.Case reports in hematology · 2013Article
- Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia.Journal of blood medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Despite recent attempts to define and classify patients with marked eosinophilia and features consistent with myeloproliferative disease, areas of controversy remain. These are particularly apparent in situations in which multiple lineages are involved in a clonal process and clinical manifestations are overlapping. Although the introduction of new molecular diagnostics and targeted therapies has begun to clarify the boundaries between some of these disorders, several questions remain with respect to the classification of patients with myeloproliferative hypereosinophilic syndrome (HES) of unknown etiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.